Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

P. Neoptolemos, John; H. Palmer, Daniel; Ghaneh, Paula; Eirini Psarelli, Eftychia; W. Valle, Juan; Halloran, Christopher; Olusesan Faluyi, Olusola; O’Reilly, Derek; Cunningham, David; Wadsley, Jonathan; Darby, Suzanne; Meyer, Tim; Gillmore, Roopinder; Anthoney, Alan; Lind, Pehr; Glimelius, Bengt; Falk, Stephen; R. Izbicki, Jakob; Middleton, Gary; Cummins, Sebastian; J. Ross, Paul; Wasan, Harpreet; McDonald, Alec; Crosby, Tom; Ting, Yuk; Patel, Kinnari; Sherriff, David; Soomal, Rubin; Borg, David; Sothi, Sharmila; Hammel, Pascal; Hackert, Thilo; Jackson, Richard; W. Büchler, Markus

doi:10.1016/s0140-6736(16)32409-6

Public

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Published in The Lancet • Jan 24, 2017

Authors:

John P. Neoptolemos

Daniel H. Palmer

Paula Ghaneh

Abstract

Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better survival and tumour response with gemcit...

Subject

Gemcitabine

Capecitabine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!